Navigation Links
OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
Date:9/30/2009

ry promising results, as standard platinum, 5-FU, and radiation-based regimens for this disease are accompanied by a high incidence of severe radiation esophagitis, requiring patients to receive nutrition through feeding tubes," said Dr. Safran. "Paclitaxel poliglumex's selective radiation enhancement preclinical profile is being validated by the high rates of pathologic complete remission and low rates of severe regional side effects we have observed in this phase 2 study. Our results justify proceeding to a randomized, controlled trial to definitively prove the impressive clinical benefit we have observed in our experience with this novel bioengineered paclitaxel agent," Dr. Safran added.

"We look forward to discussing with the Food and Drug Administration a potential phase III registration strategy for this indication," said Jack Singer, M.D., Chief Medical Officer at CTI. "This would be the first registration study for a radiation sensitizing agent in this indication."

Concurrent chemotherapy with 50.5 Gy of radiation is the standard pre-surgical therapy for patients with potentially resectable, locally-advanced esophageal cancer. Although the addition of chemotherapy to radiation is beneficial, the cure rate for esophageal cancer is low. Standard neoadjuvant treatment for esophageal cancer uses a regimen of cisplatin, and fluorouracil (5-FU) chemotherapy with concurrent radiation, which is a regimen associated with a high incidence of Grade 3-4 toxicity to the upper gastrointestinal track necessitating prophylactic insertion of feeding tubes. Published preclinical studies have demonstrated that, unlike standard paclitaxel and other chemotherapeutic agents that enhance radiation killing by a factor of 1.5 to 2.0, OPAXIO increases tumor specific radiation cell kill by a factor of 7.2 to 8.4-fold (Milas Luka et al, Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability, Int'l J. Radiat. Oncol. Biol. Ph
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
3. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
6. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
7. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
8. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
9. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
10. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... on Thursday, August 7, 2014 before markets open. The ... conference call at 8:00 a.m. Eastern time (5:00 a.m. ... call and webcast to discuss financial results and recent ... calling (800) 708-4540 (domestic) or (847) 619-6397 (international), participant ...
(Date:7/31/2014)... India , July 31, 2014 ... Inc. announced today that they recently entered into ... European Union and certain other European countries, for ... post-surgical pain management. Cipla intends to launch the ... its own label into the German market late ...
(Date:7/31/2014)... and NOTTINGHAM, England ... Inc. (NASDAQ: CBRX ) today announced ... Ltd., have announced a collaboration that will support ... and formulation development stage.  Molecular Profiles, pharmaceutical development ... preclinical drug metabolism and pharmacokinetics (DMPK) to give ...
Breaking Medicine Technology:Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Cipla and BioQuiddity Announce EU Commercial Partnership for OneDose-ReadyfusOR for Post-Surgical Pain Management 2Cipla and BioQuiddity Announce EU Commercial Partnership for OneDose-ReadyfusOR for Post-Surgical Pain Management 3Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis 2Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis 3
... Awarepoint Corporation , the leading provider ... health care, and MEDITECH , a leading ... announced a collaboration to integrate technologies to provide ... critical milestone tracking within MEDITECH,s enterprise-wide electronic health ...
... Company (Nasdaq: PRGO ; TASE) today announced that ... 2012 on Thursday, October 27, 2011 at approximately 8:00 a.m. ... a.m. (ET) hosted by Joseph C. Papa, Perrigo,s Chairman and ... available live via webcast to interested parties on the Perrigo ...
Cached Medicine Technology:Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms 2Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms 3
(Date:7/31/2014)... July 31, 2014 My Mobile ... strategic alliance with Dr. Lawrence Wasserman, Managing Director, ... to http://www.mymobileuni.com its global health and ... will include courses, e-books and other digital ... learn, re-skill or up-skill themselves in the health ...
(Date:7/31/2014)... 2014 The North American Colorants ... in North America with analysis and forecast of ... the North American Colorants Market report, to get ... also provides a glimpse of the segmentation in ... by various tables and figures. , http://www.micromarketmonitor.com/market/americas-colorants-8463333110.html ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... business-to-business publication dedicated to delivering cutting-edge information ... biopharmaceuticals and therapeutics, recently launched its newly ... new website optimizes navigation by providing visitors ... manufacturing, analytical and strategic business areas. As ...
(Date:7/31/2014)... (HealthDay News) -- A new report finds that by 2010, ... office involved diabetes, with the greatest rise among those aged ... Disease Control and Prevention found the number of office visits ... 34 percent between 2005 and 2010. Almost 29 million ... sugar disease costs almost $245 billion each year. Diabetes falls ...
(Date:7/31/2014)... (HealthDay News) -- The virus that causes cold sores -- ... absence of symptoms, according to a new study. ... cells of people infected with the virus. This explains why ... why others get them only occasionally. The authors said the ... "We thought when the disease was dormant, it was ...
Breaking Medicine News(10 mins):Health News:MyMobileUniversity and Fortech International Form Strategic Alliance That Will Enhance the Global Health and Medical Channel on Its Website 2Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:BioProcess International Launches New Website 2Health News:Big Jump in Doctor's Office Visits for Young Adults With Diabetes 2Health News:Cold Sore Virus Active Without Symptoms, Study Finds 2
... YORK, Sept. 3 Reportlinker.com announces that a new market research report ... Cosmetic Surgery Markets: Products and Services , , ... , , , The ... figure that is expected to reach $40.1 billion in 2013, for a ...
... YORK, Sept. 3 As millions of teens head back to school, ... , Teens are at a greater risk of than any ... lack of experience. Many of those crashes could be avoided with proper ... produces free driver education programs. , , NRSF spokesperson ...
... PHOENIX, Sept. 3 Maldonado Medical, a Durable ... in continuing its commitment to physicians, patients and the ... (AMA) and other physician associations from several states in ... is against the following health insurers: Aetna Inc., Cigna ...
... The September issue of European Urology , ... features an article and a video in the Surgery ... showing that the periurethral suspension technique results in significantly ... radical prostatectomy (RALP). RALP is a widespread and ...
... 2009) National Cancer Institute (NCI) has renewed a ... in prevention, diagnosis and treatment of ovarian cancer, which ... the University of Pennsylvania. First approved in 1999, ... Chase-Penn Ovarian SPORE. "The SPORE program has always been ...
... , CLEVELAND, Sept. 3 At a time ... with the costs of prescription medications, supermarket retailer Giant Eagle, ... 46 common dosages available for free every day at all ... initiative begins today, Thursday, September 3, with a 10:15 AM ...
Cached Medicine News:Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 2Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 3Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 4Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 5Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 6Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 7Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 8Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 9Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 10Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 11Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 12Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 13Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 14Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 15Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 16Health News:Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report 17Health News:Back to School Brings Risks to Young Drivers; Traffic Crashes Leading Cause of Teen Death, Says National Road Safety Foundation 2Health News:Maldonado Medical LLC Champions Physician & Patient Rights for Better Reimbursement Schedules Nationwide 2Health News:Maldonado Medical LLC Champions Physician & Patient Rights for Better Reimbursement Schedules Nationwide 3Health News:Maldonado Medical LLC Champions Physician & Patient Rights for Better Reimbursement Schedules Nationwide 4Health News:NCI renews Fox Chase / Penn Ovarian Cancer 'SPORE' grant for a third 5-year term 2Health News:NCI renews Fox Chase / Penn Ovarian Cancer 'SPORE' grant for a third 5-year term 3Health News:NCI renews Fox Chase / Penn Ovarian Cancer 'SPORE' grant for a third 5-year term 4Health News:Giant Eagle Pharmacy to Offer Customers in Ohio a Dose of Economic Relief Through Free Antibiotics Program 2Health News:Giant Eagle Pharmacy to Offer Customers in Ohio a Dose of Economic Relief Through Free Antibiotics Program 3
... The Coolscope operates with a simple ... monitor display. Direct the mouse cursor ... macro image of the slide and ... The intuitive Graphic User Interface (GUI) ...
The simplest, neatest, most efficient anti-theft system for frames and sunwear. Available in 3 colors Black, Matte aluminum, and Bronze. Fits with any style or color of furniture. Safe, simple, easy...
Counter top frosted acrylic 4 frame display....
Stainless steel lockable wall display for up to 12 frames....
Medicine Products: